Literature DB >> 7831423

Inhibition of antidepressant demethylation and hydroxylation by fluvoxamine in depressed patients.

S Härtter1, H Wetzel, E Hammes, C Hiemke.   

Abstract

Bidirectional drug interactions between fluvoxamine and classical antidepressants were studied in depressed patients. A column switching technique combined with high performance liquid chromatography (HPLC) enabled automated analyses of plasma for simultaneous determination of fluvoxamine, tricyclic and tetracyclic antidepressants and demethylated and major hydroxylated metabolites in a single HPLC run. The measurements revealed that fluvoxamine inhibited N-demethylation of imipramine, clomipramine, amitriptyline and maprotiline whereas interferences with hydroxylation reactions were restricted to aromatic 8-hydroxylation of clomipramine. In patients under fluvoxamine monotherapy before comedication, plasma concentrations of fluvoxamine increased after administration of a tricyclic antidepressant, thus indicating bidirectional drug interactions. The inhibitory effects of fluvoxamine on the metabolism of classical antidepressants disappeared after discontinuation of concomitant fluvoxamine treatment within at least 1-2 weeks. The reported alterations in drug metabolism observed in depressed patients who were under fluvoxamine/tricyclic antidepressant comedication suggested that careful supervision and regular drug monitoring are necessary in such patients.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7831423     DOI: 10.1007/bf02251285

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  24 in total

1.  Fluoxetine-induced elevation and prolongation of tricyclic levels in overdose.

Authors:  D L Rosenstein; J Takeshita; J C Nelson
Journal:  Am J Psychiatry       Date:  1991-06       Impact factor: 18.112

2.  Fluoxetine and norfluoxetine are potent inhibitors of P450IID6--the source of the sparteine/debrisoquine oxidation polymorphism.

Authors:  K Brøsen; E Skjelbo
Journal:  Br J Clin Pharmacol       Date:  1991-07       Impact factor: 4.335

3.  Fluvoxamine-tricyclic antidepressant interaction. An accidental finding.

Authors:  G Bertschy; S Vandel; B Vandel; G Allers; R Volmat
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

Review 4.  The safety of fluoxetine--an update.

Authors:  G L Cooper
Journal:  Br J Psychiatry Suppl       Date:  1988-09

5.  Elevated antidepressant plasma levels after addition of fluoxetine.

Authors:  A B Aranow; J I Hudson; H G Pope; T A Grady; T A Laage; I R Bell; J O Cole
Journal:  Am J Psychiatry       Date:  1989-07       Impact factor: 18.112

6.  Comparison of the metabolism of the three antidepressants amitriptyline, imipramine, and chlorimipramine in vitro in rat liver microsomes.

Authors:  R Krüger; G Hölzl; H J Kuss; L Schefold
Journal:  Psychopharmacology (Berl)       Date:  1986       Impact factor: 4.530

7.  Electrocardiographic changes with nortriptyline and 10-hydroxynortriptyline in elderly depressed outpatients.

Authors:  L S Schneider; T B Cooper; J A Severson; T Zemplenyi; R B Sloane
Journal:  J Clin Psychopharmacol       Date:  1988-12       Impact factor: 3.153

Review 8.  Catecholoestrogens (2-and 4-hydroxyoestrogens): chemistry, biogenesis, metabolism, occurrence and physiological significance.

Authors:  P Ball; R Knuppen
Journal:  Acta Endocrinol Suppl (Copenh)       Date:  1980

9.  A preliminary, open study of the combination of fluoxetine and desipramine for rapid treatment of major depression.

Authors:  J C Nelson; C M Mazure; M B Bowers; P I Jatlow
Journal:  Arch Gen Psychiatry       Date:  1991-04

10.  Review of the animal pharmacology and pharmacokinetics of fluvoxamine.

Authors:  V Claassen
Journal:  Br J Clin Pharmacol       Date:  1983       Impact factor: 4.335

View more
  13 in total

Review 1.  The impact of the CYP2D6-polymorphism on dose recommendations for current antidepressants.

Authors:  Norbert Thuerauf; Jens Lunkenheimer
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2006-08       Impact factor: 5.270

Review 2.  The impact of sex as a biological variable in the search for novel antidepressants.

Authors:  Alexia V Williams; Brian C Trainor
Journal:  Front Neuroendocrinol       Date:  2018-05-31       Impact factor: 8.606

Review 3.  Metabolism of the newer antidepressants. An overview of the pharmacological and pharmacokinetic implications.

Authors:  S Caccia
Journal:  Clin Pharmacokinet       Date:  1998-04       Impact factor: 6.447

Review 4.  How important are gender differences in pharmacokinetics?

Authors:  Bernd Meibohm; Ingrid Beierle; Hartmut Derendorf
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

Review 5.  Clinically significant drug interactions with antidepressants in the elderly.

Authors:  Edoardo Spina; Maria Gabriella Scordo
Journal:  Drugs Aging       Date:  2002       Impact factor: 3.923

Review 6.  The Role of Metabolites of Antidepressants in the Treatment of Depression.

Authors:  M V Rudorfer; W Z Potter
Journal:  CNS Drugs       Date:  1997-04       Impact factor: 5.749

7.  Polymorphism of human cytochrome P450 2D6 and its clinical significance: part II.

Authors:  Shu-Feng Zhou
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

8.  Non-competitive inhibition of clomipramine N-demethylation by fluvoxamine.

Authors:  S Härtter; M Arand; F Oesch; C Hiemke
Journal:  Psychopharmacology (Berl)       Date:  1995-01       Impact factor: 4.530

Review 9.  Overview of the pharmacokinetics of fluvoxamine.

Authors:  J van Harten
Journal:  Clin Pharmacokinet       Date:  1995       Impact factor: 6.447

Review 10.  Fluvoxamine. An updated review of its pharmacology, and therapeutic use in depressive illness.

Authors:  M I Wilde; G L Plosker; P Benfield
Journal:  Drugs       Date:  1993-11       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.